Yifang Biopharma D-2570 Psoriasis Phase II Clinical Study Results Released
March 12, 2025
Source: drugdu
33
On March 10, Yifang Biopharma (688382) announced that on March 8, 2025, the Phase II clinical study results of the company's independently developed TYK2 inhibitor D-2570 for the treatment of moderate to severe plaque psoriasis were released in the form of an oral report in the latest breakthrough research abstracts section of the 2025 American Academy of Dermatology Annual Meeting.
In terms of safety, D-2570 was generally well tolerated, most adverse events were mild to moderate, and no serious adverse events were reported. Its safety profile is similar to other TYK2 inhibitors, and no new safety signals were found.
In addition, data from Phase II clinical studies showed that D-2570 is significantly better than placebo in treating patients with moderate to severe psoriasis, and is also better than similar TYK2 inhibitors currently on the market. It is also comparable in effectiveness to antibody biologics (such as anti-IL-17A and anti-IL-23 antibodies). It has good overall tolerability and is expected to provide a new treatment option for patients with autoimmune diseases, including psoriasis, in the future.
https://finance.eastmoney.com/a/202503103341047784.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- a milestone in the rise of domestic production March 12, 2025
- Heavy Ten Year Plan March 12, 2025
- Sino Biopharmaceuticals and Qingpu Biotechnology Reach Exclusive Cooperation Agreement March 12, 2025
- Sino Biopharmaceutical’s innovative drug clinical research results are internationally recognized March 12, 2025
- When will the HPV vaccine be free? NPC deputies call on the central government to support the vaccination of vulnerable groups March 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
